A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain

Inclusion Criteria: * Healthy male volunteers between 18 and 40 years of age * BMI between ≥ 18 and ≤ 25 * Able to provide written informed consent * Routine clinical laboratory tests either within normal limits or not clinically meaningful if outside of normal limits Exclusion Criteria: * History of Cushing's syndrome or Addison's disease * Prior or current history of any psychiatric disorder, including eating disorders such as anorexia nervosa, bulimia nervosa, or binge-eating disorder * Positive urine drug screen for any non-prescribed drug of abuse (including but not limited to amphetamines, cannabinoids, barbiturates, cocaine, opiates, benzodiazepines) * Participation in a clinical investigation of any drug, biological or other investigational therapy within 30 days prior to dosing * Have a history of an allergic reaction to either mifepristone or olanzapine * Any clinically significant abnormality on screening laboratory tests * QTc Bazzett's ≥ 450 msec * Any major medical condition, which in the opinion of the Investigator would place the patient at undue risk. * Receiving any prescription or over-the-counter medications that could potentially affect appetite or weight * History of recent (within 6 months of screening) significant weight fluctuation